Short answer
Evolent Health, Inc. (EVH) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $653M (up 46.9% year over year) with net income of −$28M.
Q2 2026 key financials · XBRL
- Revenue
- $653M
- +46.9% YoY · +31.5% QoQ
- Net income
- −$28M
- −42.6% YoY · −6.5% QoQ
- Operating margin
- -1.5%
- EPS (diluted)
- −$0.25
- +43.2% YoY · −4.2% QoQ
Source: XBRL data from the Evolent Health, Inc. (EVH) Q2 2026 10-Q on SEC EDGAR. USD.
Evolent Health, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- MD&A excerpt incomplete, with no quarterly revenue, profitability, segment, cash-flow, or outlook figures provided
Risk Factors
- No Risk Factors section provided; changes from the most recent 10-K cannot be assessed
- CEO Seth Blackley 10b5-1 plan authorizes sales of 298,129 shares beginning December 15, 2026
- President Daniel McCarthy 10b5-1 plan authorizes sales of 201,320 shares beginning August 21, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Evolent Health, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.